254
Participants
Start Date
March 6, 2014
Primary Completion Date
October 24, 2016
Study Completion Date
April 26, 2017
Sym004 (12 mg/kg)
Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
Sym004 (9/6 mg/kg)
Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
Best Supportive Care (BSC)
BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
Fluorouracil (5-FU)
5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
Capecitabine
Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
ULB Hôpital Erasme, Brussels
SMZ Süd - Kaiser Franz Josef Spital Wien, Vienna
Uzsoki Utcai Korhaz, Budapest
Cliniques Universitaires Saint-Luc, Brussels
UZ Leuven, Leuven
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc
SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Nyíregyháza
Clinique et Maternité Sainte-Elisabeth, Namur
Jasz-Nagykun-Szolnok Megyei Korhaz-Rendelointezet, Szolnok
CHU Mont-Godinne, Yvoir
CHU Ambroise Paré, Mons
Universitair Ziekenhuis Gent, Ghent
Azienda Ospedaliero Universitaria San Martino, Genova
Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan
Centre Georges François Leclerc, Dijon
Hospital General Universitario Gregorio Marañon, Madrid
Centro Integral Oncologico Clara Campal, Madrid
CHU de Toulouse - Hôpital Rangueil, Toulouse
Hospital Universitario Central de Asturias, Oviedo
Groupe Hospitalier Saint André - Hôpital Saint André, Bordeaux
Florida Cancer Specialists, St. Petersburg
Florida Cancer Specialists-Broadway, Fort Myers
Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie
CRLCC Eugene Marquis, Rennes
IOV - Istituto Oncologico Veneto IRCCS, Padua
Hospital Universitario Virgen del Rocio, Seville
ICO - Site René Gauducheau, Saint-Herblain
ICO - Site Paul Papin, Angers
Azienda Ospedaliero Universitaria Pisana, Pisa
Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona
Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt
Washington University School of Medicine, St Louis
Mercy Research, Springfield
Centre Léon Bérard, Lyon
Texas Oncology, P.A., Tyler
Seconda Università degli Studi di Napoli, Napoli
Institut Sainte Catherine, Avignon
Comprehensive Cancer Centers of Nevada, Henderson
USC Norris Comprehensive Cancer Center, Los Angeles
Sharp Memorial Hospital, San Diego
"St. Petersburg SHI City Clinical Oncology Dispensary", Saint Petersburg
"BHI of Omsk region Clinical Oncology Dispensary", Omsk
Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden
Policlinico Universitario Agostino Gemelli, Roma
Presidio Ospedaliero SS. Trinità Sora, Sora
Azienda Ospedaliera S. Maria Di Terni, Terni
SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie, Olsztyn
Wielkopolskie Centrum Onkologii, Poznan
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Torun
Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw
Hospital del Mar, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clinic i Provincial de Barcelona, Barcelona
ICO l´Hospitalet - Hospital Duran i Reynals, Barcelona
Symphogen A/S
INDUSTRY